Stockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019 AusBiotech event in Melbourne.

In this episode Tim chats with CEO and MD of Dimerix, Nina Webster, and CEO of Pharmaxis, Gary Phillips.

Dimerix (ASX:DXB) focuses on chronic kidney diseases, including diabetic kidney disease.

The company’s lead drug, DMX 200, is proposed as an adjunct therapy for patients receiving irbesartan, the current standard of care treatment for kidney disease.

In the US Dimerix has ‘orphan indication” for the kidney scarring disease FSGS (focal segmental glomerulosclerosis) and is also furthering a treatment for chronic obstructive pulmonary disease.

Meanwhile, Pharmaxis (ASX:PXS) has developed a treatment for cystic fibrosis called Bronchitol, which is approved in Europe and subject to US approval.

The company is also eyeing treatments for a common liver disease called NASH – non alcoholic steatohepatitis, or ‘fatty liver disease’ – as well as diabetic retinopathy and the fatal lung disease idiopathic pulmonary fibrosis.

So tune in to hear the pair discuss developing drugs, fighting fibrosis and squeezing squishometers

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!